Quest Diagnostics ( (DGX) ) has released its Q4 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Quest Diagnostics is a leading provider of diagnostic information services, delivering insights derived from its extensive database of clinical lab results to improve health outcomes across the healthcare ecosystem.
In its latest earnings report, Quest Diagnostics announced significant financial growth with a 14.5% increase in fourth-quarter revenues, reaching $2.62 billion. The company reported a diluted earnings per share (EPS) increase of 14.7% for the same period, showcasing a robust financial performance for the end of 2024.
Key financial highlights include a full-year revenue increase of 6.7%, totaling $9.87 billion, and a full-year adjusted diluted EPS rise of 2.5% to $8.93. Quest Diagnostics also completed eight acquisitions, including LifeLabs in Canada, expanding its diagnostic portfolio and market reach. The company increased its quarterly dividend by 6.7% to $0.80 per share, reflecting strong shareholder value initiatives.
The company’s strategic growth included extending health plan access to over 90% of in-network lives nationwide and launching advanced diagnostic tests, such as Alzheimer’s disease biomarkers and the first H5 avian influenza test from a commercial lab. These efforts, coupled with automation and AI technology deployments, position Quest Diagnostics for continued growth.
Looking ahead to 2025, Quest Diagnostics anticipates further revenue and earnings growth, with projected revenues between $10.70 billion and $10.85 billion. The company remains confident in its business fundamentals and the positive momentum from recent acquisitions, guiding an adjusted diluted EPS range of $9.55 to $9.80.
